Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

被引：0
|
作者：
Ya-nan Man
Yan-fang Chen
机构：
[1] The Second Hospital of Tianjin Medical University,Department of Radiation Oncology
来源：
International Urology and Nephrology | 2019年 / 51卷
关键词：
SII; -dimer; Fibrinogen; CRPC; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2189 / 2199
页数：10
相关论文
共 50 条
  • [21] Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
    Teishima, Jun
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Hasegawa, Yasuhisa
    Kato, Masao
    Kajiwara, Mitsuru
    Shigeta, Masanobu
    Maruyama, Satoshi
    Moriyama, Hiroyuki
    Fujiwara, Seiji
    Matsubara, Akio
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (11): : E582 - E587
  • [22] Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors
    Caffo, Orazio
    Pappagallo, Giovanni
    Brugnara, Sonia
    Caldara, Alessia
    di Pasquale, Maria Chiara
    Ferro, Antonella
    Frisinghelli, Michela
    Murgia, Viviana
    Russo, Lucianna Maria
    Soini, Barbara
    Valduga, Francesco
    Veccia, Antonello
    Galligioni, Enzo
    UROLOGY, 2012, 79 (03) : 644 - 649
  • [23] Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer
    Anton, Angelyn
    Pillai, Sruti
    Semira, Marie Christine
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Azad, Arun
    Kwan, Edmond M.
    Spain, Lavinia
    Gunjur, Ashray
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Baenziger, Olivia
    Gibbs, Peter
    Tran, Ben
    BJUI COMPASS, 2022, 3 (03): : 205 - 213
  • [24] Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
    Maroto, Pablo
    Solsona, Eduardo
    Gallardo, Enrique
    Mellado, Begona
    Morote, Juan
    Angel Arranz, Jose
    Gomez-Veiga, Francisco
    Unda, Miguel
    Angel Climent, Miguel
    Alcaraz, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 127 - 136
  • [25] Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide
    Caffo, Orazio
    Basso, Umberto
    Cattrini, Carlo
    Ermacora, Paola
    Maruzzo, Marco
    Alberti, Martina
    Anesi, Cecilia
    Bimbatti, Davide
    Cani, Massimiliano
    Crespi, Veronica
    Farinea, Giovanni
    Kadrija, Dzenete
    Kinspergher, Stefania
    Lai, Eleonora
    Lay, Ludovica
    Maines, Francesca
    Mennitto, Alessia
    Pierantoni, Francesco
    Samuelly, Alessandro
    Urban, Susanna
    Buttigliero, Consuelo
    Veccia, Antonello
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [26] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Gross-Goupil, Marine
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 114 - 114
  • [27] TREATMENT EFFECT AND COSTS OF THE COMPLETE THERAPEUTIC PATHWAY IN PATIENTS WITH FIRST-LINE CASTRATION-RESISTANT PROSTATE CANCER WITH EITHER FIRST-LINE DOCETAXEL OR ABIRATERONE ACETATE PLUS PREDNISONE
    Holleman, M. S.
    Santi, I
    Huygens, S.
    Aben, K. K. H.
    Van den Bergh, A. C. M.
    Bergman, A. M.
    van den Eertwegh, A. J. M.
    Kuppen, M. C. P.
    Lavalaye, J.
    Mehra, N. M.
    van Moorselaar, R. J. A.
    Van Oort, I. M.
    Somford, D. M.
    Westgeest, H. M.
    Gerritsen, W. R.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2022, 25 (01) : S266 - S267
  • [28] Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
    Stuhler, Viktoria
    Herrmann, Lisa
    Rausch, Steffen
    Stenzl, Arnulf
    Bedke, Jens
    CANCERS, 2022, 14 (12)
  • [29] EQ-5D UTILITY INDEX IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH PROGRESSION DURING OR AFTER FIRST-LINE DOCETAXEL THERAPY
    James, N.
    Eisenberger, M.
    Fizazi, K.
    Heidenreich, A.
    Joulain, F.
    Laizet, C.
    VALUE IN HEALTH, 2011, 14 (07) : A457 - A458
  • [30] Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer
    Rajwa, Pawel
    Schuettfort, Victor M.
    D'Andrea, David
    Quhal, Fahad
    Mori, Keiichiro
    Katayama, Satoshi
    Laukhtina, Ekaterina
    Pradere, Benjamin
    Motlagh, Reza Sari
    Mostafaei, Hadi
    Grossmann, Nico C.
    Huebner, Nicolai
    Aulitzky, Andreas
    Mun, Dong-Ho
    Briganti, Alberto
    Karakiewicz, Pierre, I
    Fajkovic, Harun
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (11) : 785.e19 - 785.e27
12345